Released Aug 4, 2021, after the close
10-Q filed Aug 4, 2021, 35 days after period end · 0001564590-21-040821
Q2 2021 · 10-Q
Revenue$13.41M$13.41M +145.4% vs Q2 2020+20.4% vs Q1 2021
Net Income-$55.13M-$55.13M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.58-$0.58 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$46,779,000N/M
Operating Cash Flowderived-$32,106,000N/M
Free Cash Flowderived-$45,725,000N/M
Margins · derived
Operating margin-348.8%+176.5 pt vs Q2 2020
Net margin-411.1%+102.6 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $13.41M | $5.47M | $2.82M | $1.03M |
| Net Income | -$55.13M | -$28.07M | -$23.48M | -$19.65M |
| EPS Diluted | -$0.58 | -$0.35 | -$0.36 | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR